
Ivar Hompland
- Consultant; MD, PhD
Publications 2025
A comparison of the risk prediction models PERSARC and Sarculator in patients with localized soft tissue sarcoma of the extremities and trunk wall
ESMO Open, 10 (8), 105517 (in press)
DOI 10.1016/j.esmoop.2025.105517, PubMed 40712530
Publications 2024
Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study
Acta Oncol, 63, 288-293
DOI 10.2340/1651-226X.2024.39851, PubMed 38712513
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023
Publications 2023
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor
JCO Precis Oncol, 7, e2200351
DOI 10.1200/PO.22.00351, PubMed 36724411
Ewing sarcoma of the temporal bone with aneurysmal bone cyst-like changes: A rare case report with an unusual radiological presentation
Neuroradiol J, 37 (5), 640-644
DOI 10.1177/19714009231212358, PubMed 37923348
Publications 2022
Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study
Acta Oncol, 61 (7), 793-800
DOI 10.1080/0284186X.2022.2082259, PubMed 35698755
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours
Anticancer Res, 42 (2), 955-963
DOI 10.21873/anticanres.15555, PubMed 35093895
Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity
Oncotarget, 13, 508-517
DOI 10.18632/oncotarget.28209, PubMed 35284037
Inoperable or incompletely resected craniofacial osteosarcoma treated by particle radiotherapy
Front Oncol, 12, 927399
DOI 10.3389/fonc.2022.927399, PubMed 36212490
Publications 2021
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Cancer Immunol Immunother, 70 (9), 2617-2624
DOI 10.1007/s00262-021-02876-w, PubMed 33580363
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study
Eur J Cancer, 151, 150-158
DOI 10.1016/j.ejca.2021.04.017, PubMed 33990016
Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach
Ann Surg Oncol, 28 (11), 6837-6845
DOI 10.1245/s10434-021-09605-8, PubMed 33651216
Exploring Mentorship as a Novel Approach to Improving Quality of Life in Sarcoma Survivors: A Qualitative Pilot Study
Sarcoma, 2021, 2042785
DOI 10.1155/2021/2042785, PubMed 34421328
Publications 2020
Striving towards Normality in Daily Life: A Qualitative Study of Patients Living with Metastatic Gastrointestinal Stromal Tumour in Long-Term Clinical Remission
Sarcoma, 2020, 1814394
DOI 10.1155/2020/1814394, PubMed 33082706
[Cardiac sarcoma]
Tidsskr Nor Laegeforen, 140 (6)
DOI 10.4045/tidsskr.19.0455, PubMed 32321220
Sarcoma of the heart
Tidsskr. Nor. Laegeforen., 140 (6), 582-583
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors
Clin Sarcoma Res, 10, 2
DOI 10.1186/s13569-019-0124-3, PubMed 31969978
Publications 2019
Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study
Clin Sarcoma Res, 9, 6
DOI 10.1186/s13569-019-0116-3, PubMed 31061697
Is Peritoneal Tumor Penetration of Prognostic Importance in Gastrointestinal Stromal Tumors?
Ann Surg Oncol, 26 (13), 4730-4736
DOI 10.1245/s10434-019-07813-x, PubMed 31520212
Publications 2018
Genotype and risk of tumour rupture in gastrointestinal stromal tumour
Br J Surg, 105 (2), e169-e175
DOI 10.1002/bjs.10743, PubMed 29341147
[Not Available]
Tidsskr Nor Laegeforen, 138 (15)
DOI 10.4045/tidsskr.18.0200, PubMed 30277049
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour
Br J Surg, 106 (4), 419-426
DOI 10.1002/bjs.11027, PubMed 30507040
Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study
Ann Surg Oncol, 25 (5), 1133-1139
DOI 10.1245/s10434-018-6353-5, PubMed 29435684
Pazopanib in relapsed osteosarcoma patients: report on 15 cases
Acta Oncol, 58 (1), 124-128
DOI 10.1080/0284186X.2018.1503714, PubMed 30207179
Publications 2017
Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort
Acta Oncol, 56 (10), 1317-1323
DOI 10.1080/0284186X.2017.1330555, PubMed 28557540
Publications 2016
Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
Clin Sarcoma Res, 6, 21
DOI 10.1186/s13569-016-0062-2, PubMed 27999655
Publications 2015
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
Anticancer Res, 35 (11), 5759-65
PubMed 26503996
[A boy with a wound on his finger that would not heal]
Tidsskr Nor Laegeforen, 135 (5), 445-8
DOI 10.4045/tidsskr.14.0759, PubMed 25761032
A boy with a wound on his finger that would not heal
Tidsskr. Nor. Laegeforen., 135 (5), 444-447